Oral News and Research

RSS

Individuals with poor oral hygiene at increased risk of heart disease

Individuals who have poor oral hygiene have an increased risk of heart disease compared to those who brush their teeth twice a day, finds research published today on BMJ.com.

28 May 2010

Use of lubricants with anal sex associated with increased risk of rectal sexually transmitted infections

The risk of acquiring HIV through unprotected anal sex is at least 20 times greater than with unprotected vaginal sex and increases if other infections are already present in the rectal lining. Could the use of lubricants - at least certain kinds - be another risk factor among men and women who engage in receptive anal intercourse? Two studies presented today at the International Microbicides Conference in Pittsburgh, suggest the answer is yes.

27 May 2010

Use of bisphosphonates associated with risk of developing BON after dental surgery: Study

People undergoing bisphosphonate therapy to prevent or treat osteoporosis (a thinning of the bones) may be unfamiliar with the drug and possible adverse side effects on oral health, according to a study in the May issue of The Journal of the American Dental Association.

27 May 2010

Mayo Clinic research reveals increase in incidence of rheumatoid arthritis in women

The incidence of rheumatoid arthritis (RA) in women has risen during the period of 1995 to 2007, according to a newly published study by researchers from the Mayo Clinic. This rise in RA follows a 4-decade period of decline and study authors speculate environmental factors such as cigarette smoking, vitamin D deficiency, and lower dose synthetic estrogens in oral contraceptives may be the source of the increase.

27 May 2010

Physicians diagnose rare parasitic infection in people who consumed raw crayfish

If you're headed to a freshwater stream this summer and a friend dares you to eat a raw crayfish - don't do it. You could end up in the hospital with a severe parasitic infection.

27 May 2010

Patients with transformed lymphoma show positive response to lenalidomide: Research

New research illustrates that some patients with transformed lymphoma showed "remarkable" response to lenalidomide, an oral drug with few side effects.

27 May 2010

Head Start Dental Home Initiative launched to benefit low-income children in Illinois

The American Academy of Pediatric Dentistry today announces the launch of its Head Start Dental Home Initiative to benefit the one-in-three low-income children in the state of Illinois. The Initiative links children participating in Head Start programs to local dentists who will provide children with a "dental home" which will ensure that each child's oral health care is delivered in a comprehensive, ongoing, accessible, coordinated and family-centered way by a participating dentist.

27 May 2010

New study holds promise for patients with LCA

A new study led by Dr. Robert Koenekoop at the Montreal Children's Hospital at the McGill University Health Centre holds promise for certain patients with Leber congenital amaurosis, an inherited retinal degenerative disease that causes significant vision loss from birth. The study, sponsored by Canadian company QLT Inc., is designed to treat patients with LCA due to genetic mutations in either retinal pigment epithelium protein 65 or lecithin:retinol acyltransferase.

27 May 2010

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.

27 May 2010

Important milestone in development of ORMD-0801 published in DOM journal

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects," authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and published in the Diabetes, Obesity and Metabolism journal.

26 May 2010

Perrigo acquires rights to ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Perrigo Company today announced that it has acquired rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets), indicated for the cleansing of the colon as a preparation for colonoscopy in adults.

26 May 2010

Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development

Presidio Pharmaceuticals, Inc. announced today that they have selected a second clinical candidate, PPI-1301, from their hepatitis C virus (HCV) NS5A program for advancement into clinical development. Presidio's first NS5A inhibitor, PPI-461, is currently undergoing evaluation in a Phase 1a clinical study.

26 May 2010

Plackers to donate dental flossers to Oral Health America's Smiles Across America program

Plackers, a leading brand of consumer oral care products, has partnered with Oral Health America, the nation's leading independent organization dedicated to eliminating oral disease through access, education and advocacy, to donate dental flossers that will reach over 30,000 children in need through the Smiles Across America program.

26 May 2010

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD), according to the National Institute of Mental Health (NIMH). New data presented today show efficacy of CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) on ADHD symptoms in children with the condition who also may face other specific challenges.

26 May 2010

Highlights from June 2010 issue of American Journal of Pathology

Dr. Kanneboyina Nagaraju and colleagues at the Children's National Medical Center, Washington, DC demonstrate that affected muscle may directly contribute to inflammation in muscular dystrophy. Their report can be found in the June 2010 issue of The American Journal of Pathology.

26 May 2010

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder in adolescents aged 13 to 17 years.

26 May 2010

Defect in cellular pathways provides new explanation for earliest stages of craniosynostosis in newborns

University of Rochester Medical Center scientists discovered a defect in cellular pathways that provides a new explanation for the earliest stages of abnormal skull development in newborns, known as craniosynostosis.

26 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

GTx, Inc. today announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate.

26 May 2010

Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients

Cytochroma today announced positive Phase 1/2 results for CTAP101 Capsules, a product being developed to treat secondary hyperparathyroidism (SHPT) associated with vitamin D insufficiency in non-dialysis chronic kidney disease (CKD) patients. The study demonstrated that a single dose of CTAP101 Capsules was safe, effective and well tolerated.

25 May 2010

Oral News and Research

Individuals with poor oral hygiene at increased risk of heart disease

Use of lubricants with anal sex associated with increased risk of rectal sexually transmitted infections

Use of bisphosphonates associated with risk of developing BON after dental surgery: Study

Mayo Clinic research reveals increase in incidence of rheumatoid arthritis in women

Physicians diagnose rare parasitic infection in people who consumed raw crayfish

Patients with transformed lymphoma show positive response to lenalidomide: Research

Head Start Dental Home Initiative launched to benefit low-income children in Illinois

New study holds promise for patients with LCA

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Important milestone in development of ORMD-0801 published in DOM journal

Perrigo acquires rights to ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development

Plackers to donate dental flossers to Oral Health America's Smiles Across America program

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Highlights from June 2010 issue of American Journal of Pathology

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Defect in cellular pathways provides new explanation for earliest stages of craniosynostosis in newborns

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer

Cytochroma reports positive Phase 1/2 results for CTAP101 Capsules in non-dialysis CKD patients

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News